Literature DB >> 25399951

The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility.

Allan Joaquim Lamontanara1, Sandrine Georgeon1, Giancarlo Tria2, Dmitri I Svergun2, Oliver Hantschel3.   

Abstract

The activity of protein kinases is regulated by multiple molecular mechanisms, and their disruption is a common driver of oncogenesis. A central and almost universal control element of protein kinase activity is the activation loop that utilizes both conformation and phosphorylation status to determine substrate access. In this study, we use recombinant Abl tyrosine kinases and conformation-specific kinase inhibitors to quantitatively analyse structural changes that occur after Abl activation. Allosteric SH2-kinase domain interactions were previously shown to be essential for the leukemogenesis caused by the Bcr-Abl oncoprotein. We find that these allosteric interactions switch the Abl activation loop from a closed to a fully open conformation. This enables the trans-autophosphorylation of the activation loop and requires prior phosphorylation of the SH2-kinase linker. Disruption of the SH2-kinase interaction abolishes activation loop phosphorylation. Our analysis provides a molecular mechanism for the SH2 domain-dependent activation of Abl that may also regulate other tyrosine kinases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25399951     DOI: 10.1038/ncomms6470

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  14 in total

Review 1.  Inhibition of Nonfunctional Ras.

Authors:  Ruth Nussinov; Hyunbum Jang; Attila Gursoy; Ozlem Keskin; Vadim Gaponenko
Journal:  Cell Chem Biol       Date:  2021-01-12       Impact factor: 8.116

2.  Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface.

Authors:  John Wojcik; Allan Joaquim Lamontanara; Grzegorz Grabe; Akiko Koide; Louesa Akin; Barbara Gerig; Oliver Hantschel; Shohei Koide
Journal:  J Biol Chem       Date:  2016-02-24       Impact factor: 5.157

3.  Increasing kinase domain proximity promotes MST2 autophosphorylation during Hippo signaling.

Authors:  Thao Tran; Jaba Mitra; Taekjip Ha; Jennifer M Kavran
Journal:  J Biol Chem       Date:  2020-09-29       Impact factor: 5.157

4.  Switch-like activation of Bruton's tyrosine kinase by membrane-mediated dimerization.

Authors:  Jean K Chung; Laura M Nocka; Aubrianna Decker; Qi Wang; Theresa A Kadlecek; Arthur Weiss; John Kuriyan; Jay T Groves
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-10       Impact factor: 11.205

Review 5.  Dynamic regulatory features of the protein tyrosine kinases.

Authors:  Neha Amatya; David Yin-Wei Lin; Amy H Andreotti
Journal:  Biochem Soc Trans       Date:  2019-08-08       Impact factor: 5.407

6.  EnABLing Tumor Growth and Progression: Recent progress in unraveling the functions of ABL kinases in solid tumor cells.

Authors:  Rakshamani Tripathi; Zulong Liu; Rina Plattner
Journal:  Curr Pharmacol Rep       Date:  2018-07-23

7.  miR-452-3p Targets HDAC3 to Inhibit p65 Deacetylation and Activate the NF-κB Signaling Pathway in Early Brain Injury after Subarachnoid Hemorrhage.

Authors:  Junti Lu; Xiaodong Huang; Aiping Deng; Hong Yao; Gao Wu; Na Wang; Hui Gui; Mojie Ren; Shiwen Guo
Journal:  Neurocrit Care       Date:  2022-06-01       Impact factor: 3.532

8.  Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity.

Authors:  Sonja Lorenz; Patricia Deng; Oliver Hantschel; Giulio Superti-Furga; John Kuriyan
Journal:  Biochem J       Date:  2015-06-01       Impact factor: 3.857

Review 9.  Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK.

Authors:  Lauren E Kueffer; Raji E Joseph; Amy H Andreotti
Journal:  Front Cell Dev Biol       Date:  2021-06-23

10.  Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K.

Authors:  Afsar Ali Mian; Isabella Haberbosch; Hazem Khamaisie; Abed Agbarya; Larissa Pietsch; Elizabeh Eshel; Dally Najib; Claudia Chiriches; Oliver Gerhard Ottmann; Oliver Hantschel; Ricardo M Biondi; Martin Ruthardt; Jamal Mahajna
Journal:  Ann Hematol       Date:  2021-06-10       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.